These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35094943)

  • 21. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
    Roset M; Amonkar M; Patel R; Lara N; Kothari S
    Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy.
    Tauber M; Cohen R; Laly P; Josselin L; André T; Mekinian A
    Clin Rheumatol; 2019 Feb; 38(2):601-602. PubMed ID: 30456528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer.
    Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R
    Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
    Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.
    Gim G; Kim Y; Park Y; Kim MJ; Nam M; Yang W; Duarte SE; Jung CM; Vagia E; Viveiros P; Chae YK
    Oncologist; 2022 Jul; 27(7):525-531. PubMed ID: 35640145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Checkpoint inhibitors in colorectal carcinoma: are we entering a new era?].
    Pox C
    Inn Med (Heidelb); 2023 May; 64(5):500-505. PubMed ID: 37039887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.
    Serpas Higbie V; Rogers J; Hwang H; Qiao W; Xiao L; Dasari A; Mola-Rudd K; Morris VK; Wolff RA; Raghav K; Huey R; Parseghian C; Willis J; Kopetz S; Overman MJ; Johnson B
    Oncologist; 2022 Nov; 27(11):952-957. PubMed ID: 35946836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
    Morano F; Raimondi A; Pagani F; Lonardi S; Salvatore L; Cremolini C; Murgioni S; Randon G; Palermo F; Antonuzzo L; Pella N; Racca P; Prisciandaro M; Niger M; Corti F; Bergamo F; Zaniboni A; Ratti M; Palazzo M; Cagnazzo C; Calegari MA; Marmorino F; Capone I; Conca E; Busico A; Brich S; Tamborini E; Perrone F; Di Maio M; Milione M; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2022 May; 40(14):1562-1573. PubMed ID: 35258987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab for the treatment of colorectal cancer.
    Smith KM; Desai J
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment.
    Hong JH; Woo IS
    Cancer Lett; 2023 Jul; 565():216236. PubMed ID: 37209943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration.
    Barraud S; Tougeron D; Villeneuve L; Eveno C; Bayle A; Parc Y; Pocard M; André T; Cohen R
    Dig Liver Dis; 2023 May; 55(5):673-678. PubMed ID: 36266207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 35. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors.
    Ziranu P; Pretta A; Pozzari M; Maccioni A; Badiali M; Fanni D; Lai E; Donisi C; Persano M; Gerosa C; Puzzoni M; Bardanzellu F; Ambu R; Pusceddu V; Dubois M; Cerrone G; Migliari M; Murgia S; Spanu D; Pretta G; Aimola V; Balconi F; Murru S; Faa G; Scartozzi M
    Sci Rep; 2023 Mar; 13(1):4397. PubMed ID: 36928082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Microsatellite Instability Testing in Management of Colorectal Cancer.
    Sun BL
    Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
    Krimmel L; Quante M; Bengsch B
    Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
    Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
    Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors.
    Cancer Discov; 2018 Mar; 8(3):263. PubMed ID: 29420181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.